Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EndoEvolution LLC

Automated suturing for minimally invasive surgery

This article was originally published in Start Up

Executive Summary

Despite great strides in minimally invasive surgery over the years, suturing continues to vex surgeons. That’s understandable, given the amount of hand-eye coordination required: surgeons hold two long instruments and watch a video screen from across the room while performing very intricate motions with their hands and fingers. EndoEvolution LLC has developed an automated suturing system that mimics the way surgeons manually suture. The Endo360° uses a traditional curved needle instead of a straight needle, and it drives the needle in the exact manner a surgeon would when suturing by hand: grabbing a needle from its tail, pushing the point of the needle through the tissue and picking up the point.

You may also be interested in...



Surgical Incision Closure: Start-Ups Address A Megatrend In Health Care

Medtech start-ups are working to develop next-generation incision closure devices that address the shortfalls of gold standard sutures and staples. We profile three hopefuls in this issue: EndoEvolution, ZipLine Medical and ZSX Medical.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037784

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel